Longevity Lab Report · Public evidence card
Did a daily multivitamin prevent cancer in COSMOS?
Assessed 2026-11-15 · Main study published 2022-03-16
This card contains the public evidence assessment only.
Conclusion
COSMOS did not establish a reduction in total invasive cancer during its follow-up. This result does not settle every use of a multivitamin.
- Population and design
- 21,442 US adults: women aged 65+ and men aged 60+, without major cardiovascular disease or recently diagnosed cancer. Randomized, double-blind, placebo-controlled factorial trial.
- Studied intervention
- One daily multivitamin-mineral product (Centrum Silver); participants were also randomized to cocoa extract or its placebo.
- Comparator
- Matching multivitamin placebo.
- Measured outcome
- Total invasive cancer, excluding nonmelanoma skin cancer. Follow-up: Median 3.6 years.
- Observed result
- 518 of 10,720 versus 535 of 10,722 participants developed cancer. Hazard ratio 0.97 (95% confidence interval 0.86–1.09): the interval includes no difference.
- Main limitations
- A few years of follow-up cannot rule out a longer-term effect.
- A result for one product and older participants does not establish effects in younger people or people with a documented deficiency.
Baseline evidence assessment, not a new study or a revised library grade. This card contains no personal responses and does not recommend treatment.
Sources
- COSMOS multivitamin trial (Sesso et al., 2022)
Main study · Published 2022-03-16 · Checked 2026-11-15 · PMID 35294969
Full primary publication via indexed PMC text
- Physicians’ Health Study II (Gaziano et al., 2012)
Context · Published 2012-11-14 · Checked 2026-11-15 · PMID 23162860
Primary publication abstract and indexed results
- COSMOS investigators’ results summary
Context · Published Undated results page · Checked 2026-11-15 · Trial NCT02422745
Trial team results page; indexed text
Public card: https://longevitylabreport.com/research/multivitamin-cosmos/card
Full explainer, context and assessment history